For the almost 520,000 Americans who will undergo treatment this year, the process leaves little room for a full life. An innovative new device could change everything.
"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which promises results in 30 minutes—for myself.
In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.